Inovafirst, LLC announce a Clinical Trial for a Sleep Support Chocolate Chews

A Low Glycemic Chocolate Chew* containing Inovafirst’s time-release melatonin “Revitalizz ™”, will be tested for overall quality of sleep in individuals who suffer from chronic sleep issues.
 
 
Revitalizz Choc Chews
Revitalizz Choc Chews
 
Spread the Word
Listed Under

Tags:
Sleep
Clinical Trial

Industrys:
Food
Research

Location:
Chandler - Arizona - US

Subject:
Products

CHANDLER, Ariz. - Nov. 24, 2014 - PRLog -- A single Blind, Cross-Over Intervention Study will be Evaluating the Effects of a Newly Developed Low Glycemic, Revitalizz ™” Time-Released Melatonin Chocolate Chew.

The experimental design will address the time to fall asleep, the sleep duration and intermittent waking-ups during the sleeping period as well as alertness upon awakening.

Inovafirst, LLC, completed the first Revitalizz™ Clinical Trial comparing the proprietary blend to a commercial melatonin product having similar melatonin dosage in 2012. This trial labeled: “Sustained Release Melatonin Blend Vs. Melatonin Supplementation, Effects and Comparison on Overall Quality of Sleep, Time to Fall Asleep, Intermittent Waking-Ups, Sleep Duration and Alertness Upon Waking Up” resulted in significant improvement on the participants quality of sleep compared to the over-the-counter dietary supplement. Similar quality of sleep results are anticipated within this delivery form of a chew*.

Should you be interested in participating in the Revitalizz™ Chew study, please contact the company by email at info@revitalizz.com or visit www.revitalizz.com. For additional information regarding Inovafirst, LLC, visit www.inovafirst.com or contact Dr. Teissier Toll Free at (800) 825-1873.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Such statements are made based on management's current expectations and beliefs.  Actual results may vary from those currently anticipated based upon a number of factors.

The company undertakes no obligation to release publicly any revisions that may occur to reflect events or circumstances after the date hereof.

*These statements have not been evaluated by the Food & Drug Administration. These products are not intended to diagnose, treat or prevent any disease.

Media Contact
Dr. Teissier
***@inovafirst.com
800 825 1873
End
Source:
Email:***@inovafirst.com Email Verified
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Nov 24, 2014
Inovafirst, LLC. PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share